Your provider may adjust your dose, slow your titration, or recommend additional hydration support rather than stopping the medication
As GEP44 acts directly on muscle tissue, while its effects on islets require concomitant Y1-R antagonism, activation of Y1-R expressed in muscle tissue may ultimately prove to be a critical factor in reducing serum glucose levels, alongside any potential effects on insulin secretion and glucagon release
Once you reach your therapeutic dose, the expected rate of weight loss is 0.5-1% of your body weight per week
These timelines are subject to change based on scientific, regulatory, and market factors, as well as the capability to manufacture and distribute the drug at scale
Back in June, Novo abruptly ended a monthlong collaboration with Hims & Hers to make its weight loss drug Wegovy available on the telehealth company's platform
Before acting on mochi vs ro, keep switching, dosing, and safety decisions tied to licensed-provider review
